Form 8-K - Current report:
SEC Accession No. 0001558370-25-010658
Filing Date
2025-08-07
Accepted
2025-08-07 08:31:18
Documents
15
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mtva-20250807x8k.htm   iXBRL 8-K 47418
2 EX-99.1 mtva-20250807xex99d1.htm EX-99.1 203300
3 GRAPHIC mtva-20250807x8k001.jpg GRAPHIC 9107
4 GRAPHIC mtva-20250807xex99d1001.jpg GRAPHIC 16884
  Complete submission text file 0001558370-25-010658.txt   429460

Data Files

Seq Description Document Type Size
5 EX-101.SCH mtva-20250807.xsd EX-101.SCH 3448
6 EX-101.LAB mtva-20250807_lab.xml EX-101.LAB 15925
7 EX-101.PRE mtva-20250807_pre.xml EX-101.PRE 10052
17 EXTRACTED XBRL INSTANCE DOCUMENT mtva-20250807x8k_htm.xml XML 4806
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
MetaVia Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)